Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

BRAFV600E induces key features of LCH in iPSCs with cell type-specific phenotypes and drug responses

Giulio Abagnale, Raphaela Schwentner, Philipp Ben Soussia-Weiss, Wouter van Midden, Caterina Sturtzel, Ulrike Pötschger, Magdalena Rados, Sabine Taschner-Mandl, Ingrid Simonitsch-Klupp, Christoph Hafemeister, Florian Halbritter, Martin Distel, Sebastian Karl Eder, Caroline Hutter

Blood blood.2024026066.

https://doi.org/10.1182/blood.2024026066

Published: 2024

Includes: Supplemental data

Journal Articles

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Blood (2024) 143 (11): 1006–1017.

https://doi.org/10.1182/blood.2023020515

Published: 2024

Includes: Supplemental data

Journal Articles

Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

Lukas Kazianka, Tea Pemovska, Johannes Rohrbeck, Christoph Kornauth, Alexander Pichler, Christiane Agreiter, Simone Lubowitzki, Katharina Prochazka, Peter Neumeister, Clemens Schmitt, Richard Greil, Wolfgang Willenbacher, Dominik Wolf, Ulrich Jaeger, Ingrid Simonitsch-Klupp, Philipp Bernhard Staber

Blood (2023) 142 (Supplement 1): 5006.

https://doi.org/10.1182/blood-2023-189856

Published: 2023

Journal Articles

CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication

Marius E. Mayerhoefer, Markus Raderer, Wolfgang Lamm, Michael Weber, Barbara Kiesewetter, Johannes Rohrbeck, Ingrid Simonitsch-Klupp, Marcus Hacker, Asha Leisser, Lukas Nics, Stefan Schmitl, Hans-Juergen Wester, Alexander Haug

Blood (2022) 139 (2): 240–244.

https://doi.org/10.1182/blood.2021013239

Published: 2022

Includes: Supplemental data

Journal Articles

Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study

Ulrich Jaeger, MD, Alexander Egle, MD, Ingrid Simonitsch-Klupp, MD, Sonja Heibl, MD, Peter Neumeister, MD, Ella Willenbacher, MD, Florian Erlsbacher, Julian Larcher-Senn, Michael A. Fridrik, MD, Richard Greil, MD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-136953

Published: 2020

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Philipp Bernhard Staber, MD PhD, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, MD, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, PhD, Marius E Mayerhoefer, Richard Greil, MD, Ingrid Simonitsch-Klupp, MD, Lukas Kenner, MD, Ulrich Jaeger, MD

Blood (2019) 134 (Supplement_1): 4037.

https://doi.org/10.1182/blood-2019-129955

Published: 2019

Journal Articles

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Philipp B. Staber, Marco Herling, Mar Bellido, Eric D. Jacobsen, Matthew S. Davids, Tapan Mahendra Kadia, Andrei Shustov, Olivier Tournilhac, Emmanuel Bachy, Francesco Zaja, Kimmo Porkka, Gregor Hoermann, Ingrid Simonitsch-Klupp, Claudia Haferlach, Stefan Kubicek, Marius E. Mayerhoefer, Georg Hopfinger, Ulrich Jaeger, Claire Dearden

Blood (2019) 134 (14): 1132–1143.

https://doi.org/10.1182/blood.2019000402

Published: 2019

Journal Articles

Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication

Greiner Georg, MD PhD, Michael Gurbisz, MSc, Franz Ratzinger, MD, Nadine Witzeneder, MSc, Svenja-Verena Class, Ingrid Simonitsch-Klupp, MD, Harald Esterbauer, MD PhD, Matthias Mayerhofer, MD, Wolfgang R. Sperr, Leonhard Muellauer, MD PhD, Peter Valent, Gregor Hoermann

Blood (2018) 132 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2018-99-116492

Published: 2018

Journal Articles

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

Blood (2018) 132 (22): 2389–2400.

https://doi.org/10.1182/blood-2018-06-855502

Published: 2018

Includes: Supplemental data

Journal Articles

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Blood (2018) 132 (7): 694–706.

https://doi.org/10.1182/blood-2017-10-810739

Published: 2018

Includes: Supplemental data

Journal Articles

Essential Thrombocythemia Versus Pre-Fibrotic/Early Primary Myelofibrosis: Discrimination By Laboratory and Clinical Data

Martin Schalling, Andreas Gleiss, Bettina Gisslinger, Albert Wölfler, Veronika Buxhofer-Ausch, Georg Jeryczynski, MD, Maria-Theresa Krauth, MD, Ingrid Simonitsch-Klupp, MD, Christine Beham-Schmid, Jurgen Thiele, Heinz Gisslinger

Blood (2017) 130 (Supplement 1): 4201.

https://doi.org/10.1182/blood.V130.Suppl_1.4201.4201

Published: 2017

Journal Articles

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 855.

https://doi.org/10.1182/blood.V130.Suppl_1.855.855

Published: 2017

Journal Articles

Digital Droplet PCR: Next Generation KIT D816V Testing As Advanced Tool for Diagnosis and Prognostication in Mastocytosis

Greiner Georg, MD PhD, Michael Gurbisz, MSc, Franz Ratzinger, MD, Nadine Witzeneder, MSc, Ingrid Simonitsch-Klupp, MD, Gerlinde Mitterbauer-Hohendanner, MD, Matthias Mayerhofer, MD, Leonhard Muellauer, MD PhD, Wolfgang R. Sperr, MD, Peter Valent, MD, Gregor Hoermann, MD

Blood (2017) 130 (Supplement 1): 2927.

https://doi.org/10.1182/blood.V130.Suppl_1.2927.2927

Published: 2017

Journal Articles

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

Blood (2017) 130 (Supplement 1): 1643.

https://doi.org/10.1182/blood.V130.Suppl_1.1643.1643

Published: 2017

Journal Articles

First in Human Response of BCL-2 Inhibitor Venetoclax in T-Cell Prolymphocytic Leukemia

Bernd Boidol, Christoph Kornauth, MD, Emiel van der Kouwe, Nicole Prutsch, Lukas Kazianka, MD, Gregor Hoermann, MD, Georg Hopfinger, MD, Alexander Hauswirth, MD, Marie-Bernadette Aretin, Wolfgang R. Sperr, MD, Peter Valent, MD, Ingrid Simonitsch-Klupp, MD, Richard Morrigl, PhD, Olaf Merkel, PhD, Lukas Kenner, MD, Ulrich Jaeger, MD, Stefan Kubicek, PhD, Philipp Bernhard Staber, MD PhD

Blood (2017) 130 (Supplement 1): 575.

https://doi.org/10.1182/blood.V130.Suppl_1.575.575

Published: 2017

Journal Articles

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

Blood (2017) 130 (23): 2499–2503.

https://doi.org/10.1182/blood-2017-05-785683

Published: 2017

Includes: Supplemental data

Journal Articles

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

Barbara Kiesewetter, Ella Willenbacher, Wolfgang Willenbacher, Alexander Egle, Peter Neumeister, Daniela Voskova, Marius Erik Mayerhoefer, Ingrid Simonitsch-Klupp, Thomas Melchardt, Richard Greil, Markus Raderer

Blood (2017) 129 (3): 383–385.

https://doi.org/10.1182/blood-2016-06-720599

Published: 2017

Journal Articles

Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis

Georg Jeryczynski, MD, Albert Woelfler, MD, Bettina Gisslinger, Martin Schalling, Sonja Burgstaller, MD, Veronika Buxhofer-Ausch, Maria Theresa Krauth, MD, Klaus Geissler, MD, Ernst Schlögl, MD, Thamer Sliwa, MD, Ana-Iris Schiefer, MD, Leonhard Muellauer, MD, Ingrid Simonitsch-Klupp, MD, Christine Beham-Schmid, MD, Jürgen Thiele, MDPhD, Heinz Gisslinger

Blood (2016) 128 (22): 1932.

https://doi.org/10.1182/blood.V128.22.1932.1932

Published: 2016

Journal Articles

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

Georg Jeryczynski, MD, Bettina Gisslinger, Martin Schalling, Maria Theresa Krauth, MD, Leonhard Muellauer, MD, Ana-Iris Schiefer, MD, Christoph Kornauth, MD, Ingrid Simonitsch-Klupp, MD, Jürgen Thiele, MD PhD, Heinz Gisslinger

Blood (2016) 128 (22): 4252.

https://doi.org/10.1182/blood.V128.22.4252.4252

Published: 2016

NARROW

BRAFV600E induces key features of LCH in iPSCs with cell type-specific phenotypes and drug responses

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial

CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication

Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Essential Thrombocythemia Versus Pre-Fibrotic/Early Primary Myelofibrosis: Discrimination By Laboratory and Clinical Data

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

Digital Droplet PCR: Next Generation KIT D816V Testing As Advanced Tool for Diagnosis and Prognostication in Mastocytosis

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

First in Human Response of BCL-2 Inhibitor Venetoclax in T-Cell Prolymphocytic Leukemia

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only